1131114BLS
-
00:00
1.
Slide 0
-
00:09
2.
The many symptoms of depression …
-
00:48
3.
Slide 3
-
00:49
4.
The many symptoms of depression …
-
00:49
5.
Slide 1
-
09:54
6.
The many symptoms of depression …
-
10:16
7.
Slide 3
-
10:27
8.
Expectations of our depressed patients
-
11:02
9.
Slide 5
-
11:17
10.
Slide 6
-
11:29
11.
Slide 7
-
12:06
12.
Slide 8
-
12:10
13.
Snaith-Hamilton Pleasure Scale (SHAPS)
-
13:29
14.
Slide 10
-
15:03
15.
Which antidepressant ? Sertraline ? Bupropion ?
-
15:45
16.
The efficacy of antidepressants on anhedonia
-
16:27
17.
Slide 13
-
16:40
18.
Effects on CHEER Index (primary outcome)
-
17:03
19.
Effects on depression severity (secondary outcomes)
-
17:08
20.
Effects on anxiety severity (secondary outcomes)
-
17:12
21.
Group comparisons on CHEER index scores (primary outcome)
-
17:34
22.
Group comparisons on depression severity (secondary outcomes)
-
17:37
23.
Group comparisons on anxiety severity (secondary outcomes)
-
17:38
24.
First study (secondary outcome)
-
18:14
25.
Valdoxan: SmPC recomandations
-
18:31
26.
Slide 22
-
18:56
27.
Slide 23
-
19:11
28.
Slide 24
-
20:13
29.
Slide 25
-
20:42
30.
Slide 26
-
21:39
31.
1st reason why agomelatine improves anhedonia so fast.
-
21:47
32.
Valdoxan: A New Antidepressant With Novel Pharmacology
-
22:04
33.
Slide 29
-
22:07
34.
Slide 30
-
22:47
35.
2nd reason why agomelatine improves anhedonia so fast.
-
22:50
36.
Serotonin (5-HT) Inhibits Dopamine (DA) and Norepinephrine (NE) Release via 5-HT2C Receptors
-
23:15
37.
Ago ↓ Stress-induced glutamate release
-
24:01
38.
Agomelatine: potential impacts on glutamatergic neurotransmission
-
25:07
39.
1. Delayed onset of action of monoaminergic antidepressant.2. Star*D SSRI treatment for 14 weeks, remission rate around 30% (1st treatment level)
-
26:05
40.
3rd reason why agomelatine improves anhedonia so fast.
-
26:09
41.
Slide 37
-
27:01
42.
Slide 38
-
28:22
43.
4th reason why agomelatine improves anhedonia so fast.
-
28:23
44.
Slide 40
-
29:58
45.
Slide 41
-
32:07
46.
Slide 42
-
33:07
47.
Slide 43
-
34:56
48.
Slide 44
-
35:03
49.
Slide 45
-
35:44
50.
A further possible reason : it is about anxiety
-
35:49
51.
Anxious Distress: A New Specifier for MDD
-
36:01
52.
MDD with anxiety symptoms were associated with early onset, poor course and functioning
-
36:13
53.
Remission Rates With Antidepressant Treatment in Anxious vs Nonanxious Depression
-
36:27
54.
Anxiety depression is the hurdle for MDD remission. Sensitive to drugs’ side effects
-
36:47
55.
Agomelatine versus SSRI/SNRI
-
37:20
56.
Anxiety depression is the hurdle for MDD remission. Sensitive to drugs’ side effects
-
37:21
57.
Remission Rates With Antidepressant Treatment in Anxious vs Nonanxious Depression
-
37:21
58.
Anxiety depression is the hurdle for MDD remission. Sensitive to drugs’ side effects
-
37:23
59.
Agomelatine versus SSRI/SNRI
-
37:35
60.
Anxiety enhances- acute exposure of SSRI
-
38:16
61.
The underlying mechanism
-
39:55
62.
Extended amygdala
-
40:27
63.
Anxiety and fear-promoting circuit in the extended amygdala
-
40:57
64.
Slide 56
-
41:50
65.
Anxiety and fear-promoting circuit in the extended amygdala
-
42:45
66.
Anxiety and fear-promoting circuit in the extended amygdala
-
42:56
67.
Slide 59
-
42:56
68.
Anxiety and fear-promoting circuit in the extended amygdala
-
43:04
69.
Slide 59
-
44:04
70.
Slide 60
-
44:11
71.
Slide 61
-
44:24
72.
Slide 62
-
44:43
73.
Slide 63
-
44:54
74.
Slide 64
-
45:07
75.
Slide 65
-
45:42
76.
Slide 66
-
46:08
77.
2016 CANMAT GuidelinesAgomelatine recommended as a first line antidepressant
-
46:39
78.
Slide 68
-
46:52
79.
Valdoxan provides combinedgood efficacy with the best acceptability
-
47:34
80.
Slide 70
-
47:44
81.
Slide 71
-
48:11
82.
Case sharing
-
48:47
83.
Slide 73
-
49:16
84.
Thanks for your attention
-
50:17
85.
Slide 0
- 索引
- 筆記
- 討論
- 全螢幕
Valdoxan antidepressant efficacy for anhedonia in major depression (3)
長度: 54:58, 瀏覽: 2210, 最近修訂: 2019-11-17
-
00:00
1.
Slide 0
-
00:09
2.
The many symptoms of depression …
-
00:48
3.
Slide 3
-
00:49
4.
The many symptoms of depression …
-
00:49
5.
Slide 1
-
09:54
6.
The many symptoms of depression …
-
10:16
7.
Slide 3
-
10:27
8.
Expectations of our depressed patients
-
11:02
9.
Slide 5
-
11:17
10.
Slide 6
-
11:29
11.
Slide 7
-
12:06
12.
Slide 8
-
12:10
13.
Snaith-Hamilton Pleasure Scale (SHAPS)
-
13:29
14.
Slide 10
-
15:03
15.
Which antidepressant ? Sertraline ? Bupropion ?
-
15:45
16.
The efficacy of antidepressants on anhedonia
-
16:27
17.
Slide 13
-
16:40
18.
Effects on CHEER Index (primary outcome)
-
17:03
19.
Effects on depression severity (secondary outcomes)
-
17:08
20.
Effects on anxiety severity (secondary outcomes)
-
17:12
21.
Group comparisons on CHEER index scores (primary outcome)
-
17:34
22.
Group comparisons on depression severity (secondary outcomes)
-
17:37
23.
Group comparisons on anxiety severity (secondary outcomes)
-
17:38
24.
First study (secondary outcome)
-
18:14
25.
Valdoxan: SmPC recomandations
-
18:31
26.
Slide 22
-
18:56
27.
Slide 23
-
19:11
28.
Slide 24
-
20:13
29.
Slide 25
-
20:42
30.
Slide 26
-
21:39
31.
1st reason why agomelatine improves anhedonia so fast.
-
21:47
32.
Valdoxan: A New Antidepressant With Novel Pharmacology
-
22:04
33.
Slide 29
-
22:07
34.
Slide 30
-
22:47
35.
2nd reason why agomelatine improves anhedonia so fast.
-
22:50
36.
Serotonin (5-HT) Inhibits Dopamine (DA) and Norepinephrine (NE) Release via 5-HT2C Receptors
-
23:15
37.
Ago ↓ Stress-induced glutamate release
-
24:01
38.
Agomelatine: potential impacts on glutamatergic neurotransmission
-
25:07
39.
1. Delayed onset of action of monoaminergic antidepressant.2. Star*D SSRI treatment for 14 weeks, remission rate around 30% (1st treatment level)
-
26:05
40.
3rd reason why agomelatine improves anhedonia so fast.
-
26:09
41.
Slide 37
-
27:01
42.
Slide 38
-
28:22
43.
4th reason why agomelatine improves anhedonia so fast.
-
28:23
44.
Slide 40
-
29:58
45.
Slide 41
-
32:07
46.
Slide 42
-
33:07
47.
Slide 43
-
34:56
48.
Slide 44
-
35:03
49.
Slide 45
-
35:44
50.
A further possible reason : it is about anxiety
-
35:49
51.
Anxious Distress: A New Specifier for MDD
-
36:01
52.
MDD with anxiety symptoms were associated with early onset, poor course and functioning
-
36:13
53.
Remission Rates With Antidepressant Treatment in Anxious vs Nonanxious Depression
-
36:27
54.
Anxiety depression is the hurdle for MDD remission. Sensitive to drugs’ side effects
-
36:47
55.
Agomelatine versus SSRI/SNRI
-
37:20
56.
Anxiety depression is the hurdle for MDD remission. Sensitive to drugs’ side effects
-
37:21
57.
Remission Rates With Antidepressant Treatment in Anxious vs Nonanxious Depression
-
37:21
58.
Anxiety depression is the hurdle for MDD remission. Sensitive to drugs’ side effects
-
37:23
59.
Agomelatine versus SSRI/SNRI
-
37:35
60.
Anxiety enhances- acute exposure of SSRI
-
38:16
61.
The underlying mechanism
-
39:55
62.
Extended amygdala
-
40:27
63.
Anxiety and fear-promoting circuit in the extended amygdala
-
40:57
64.
Slide 56
-
41:50
65.
Anxiety and fear-promoting circuit in the extended amygdala
-
42:45
66.
Anxiety and fear-promoting circuit in the extended amygdala
-
42:56
67.
Slide 59
-
42:56
68.
Anxiety and fear-promoting circuit in the extended amygdala
-
43:04
69.
Slide 59
-
44:04
70.
Slide 60
-
44:11
71.
Slide 61
-
44:24
72.
Slide 62
-
44:43
73.
Slide 63
-
44:54
74.
Slide 64
-
45:07
75.
Slide 65
-
45:42
76.
Slide 66
-
46:08
77.
2016 CANMAT GuidelinesAgomelatine recommended as a first line antidepressant
-
46:39
78.
Slide 68
-
46:52
79.
Valdoxan provides combinedgood efficacy with the best acceptability
-
47:34
80.
Slide 70
-
47:44
81.
Slide 71
-
48:11
82.
Case sharing
-
48:47
83.
Slide 73
-
49:16
84.
Thanks for your attention
-
50:17
85.
Slide 0
- 位置
-
- 資料夾名稱
- 保健中心
- 發表人
- 江堤莊
- 單位
- 台大醫學院資訊組
- 建立
- 2019-11-17 17:19:47
- 最近修訂
- 2019-11-17 18:51:42
- 長度
- 54:58